Literature DB >> 22395062

Nonalcoholic fatty liver disease: multimodal treatment options for a pathogenetically multiple-hit disease.

Stergios A Polyzos1, Jannis Kountouras, Christos Zavos, Georgia Deretzi.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) has emerged as a significant public health problem. Besides the liver, NAFLD is also associated with increased cardiovascular and overall morbidity and mortality. NAFLD warrants intensive research, because no treatment has been established as yet. This may be partly attributed to the fact that the majority of the relative clinical trials have a monotherapeutic direction. However, the multifactorial pathogenesis of NAFLD may probably direct clinical trials to a combined therapeutic approach. The aim of this review is to provide a description of the multifactorial pathogenesis of NAFLD and type II diabetes mellitus-NAFLD interplay, and to summarize the therapeutic trials focusing on the combined NAFLD treatment, providing a link between the multiple-hit pathogenesis and the multimodal treatment of NAFLD patients. A diabetes-like therapeutic approach for NAFLD is finally proposed.

Entities:  

Mesh:

Year:  2012        PMID: 22395062     DOI: 10.1097/MCG.0b013e31824587e0

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  34 in total

1.  Periostin on the road to nonalcoholic fatty liver disease.

Authors:  Stergios A Polyzos; Athanasios D Anastasilakis
Journal:  Endocrine       Date:  2015-11-19       Impact factor: 3.633

Review 2.  Recent advances in dietary supplementation, in treating non-alcoholic fatty liver disease.

Authors:  Tannaz Eslamparast; Sareh Eghtesad; Hossein Poustchi; Azita Hekmatdoost
Journal:  World J Hepatol       Date:  2015-02-27

Review 3.  Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease.

Authors:  Silvia Marinho Ferolla; Geyza Nogueira de Almeida Armiliato; Cláudia Alves Couto; Teresa Cristina Abreu Ferrari
Journal:  World J Hepatol       Date:  2015-03-27

4.  Association between circulating irisin and homocysteine in patients with nonalcoholic fatty liver disease.

Authors:  Stergios A Polyzos; Jannis Kountouras; Athanasios D Anastasilakis; Anastasia Margouta; Christos S Mantzoros
Journal:  Endocrine       Date:  2014-11-09       Impact factor: 3.633

5.  Mechanisms of Evolutionary Innovation Point to Genetic Control Logic as the Key Difference Between Prokaryotes and Eukaryotes.

Authors:  William Bains; Dirk Schulze-Makuch
Journal:  J Mol Evol       Date:  2015-07-25       Impact factor: 2.395

6.  Chlorogenic acid alleviates autophagy and insulin resistance by suppressing JNK pathway in a rat model of nonalcoholic fatty liver disease.

Authors:  Hua Yan; Yan-Qiong Gao; Ying Zhang; Huan Wang; Gui-Sheng Liu; Jian-Yuan Lei
Journal:  J Biosci       Date:  2018-06       Impact factor: 1.826

7.  Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver disease.

Authors:  Stergios A Polyzos; Athanasios D Anastasilakis; Jannis Kountouras; Polyzois Makras; Athanasios Papatheodorou; Panagiotis Kokkoris; Grigorios T Sakellariou; Evangelos Terpos
Journal:  J Bone Miner Metab       Date:  2015-06-09       Impact factor: 2.626

Review 8.  Importance of imaging and recent developments in diagnosis of nonalcoholic fatty liver disease.

Authors:  Mustafa Koplay; Mesut Sivri; Hasan Erdogan; Alaaddin Nayman
Journal:  World J Hepatol       Date:  2015-04-18

9.  Activin A and follistatin in patients with nonalcoholic fatty liver disease.

Authors:  Stergios A Polyzos; Jannis Kountouras; Athanasios D Anastasilakis; Georgios Α Triantafyllou; Christos S Mantzoros
Journal:  Metabolism       Date:  2016-07-25       Impact factor: 8.694

10.  Autophagy deficiency by hepatic FIP200 deletion uncouples steatosis from liver injury in NAFLD.

Authors:  Di Ma; Matthew M Molusky; Jianrui Song; Chun-Rui Hu; Fang Fang; Crystal Rui; Anna V Mathew; Subramaniam Pennathur; Fei Liu; Ji-Xin Cheng; Jun-Lin Guan; Jiandie D Lin
Journal:  Mol Endocrinol       Date:  2013-08-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.